Performance and Safety Assessment of the Mechanical Decongestant Seawater Spray Enriched With Essential Oils From Laboratoires Gilbert in Patient With Acute Rhinitis Associated With Nasal Obstruction (DEMECA)

Prospective Multicenter Clinical Investigation to Evaluate the Performance and the Safety of the Mechanical Decongestant Seawater Spray Enriched With Essential Oils From Laboratoires Gilbert (DEMECA)

The purpose of this post-market clinical investigation is to assess the performance and the safety of the mechanical decongestant seawater spray enriched with essential oils from Laboratoires Gilbert. The study will evaluate the results of the spray on the acute rhinitis with nasal obstruction over a 7 days period.

Study Overview

• Status: Recruiting
• Conditions: Allergic Rhinitis; Nasal Obstruction; Rhinosinusitis; Rhinopharyngitis; Acute Rhinitis

• Study Type: Observational
• Enrollment (Estimated): 114

Contacts and Locations

• Study Contact: Name: Léa RADDAY; Phone Number: +33 (0)2 31 47 16 61; Email: lradday@labogilbert.fr

Study Locations

• France
  • Bayeux, France, 14400
    • Not yet recruiting
    • Pharmacie du Pont Saint Jean
    • Contact: Dr. Matthieu CHAUVIN; Phone Number: +33 (0)231920763; Email: matthieu.chauvin@yahoo.fr
  • Caen, France, 14000
    • Recruiting
    • Pharmacie de la Guérinière
    • Contact: Benjamin BEAUCHENE, Dr; Phone Number: +33 (0)2 31 82 39 80; Email: pharmaciedelagueriniere@gmail.com
    • Principal Investigator: Benjamin BEAUCHENE, Dr
  • La Force, France, 24130
    • Not yet recruiting
    • Pharmacie de la Force
    • Contact: Dr Maxime DELARUE; Phone Number: +335-53-58-94-44; Email: pharmaciedelaforce@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Participation in the study is open to patients who buy the mechanical decongestant seawater spray on request or on the advice of their pharmacist. Patients are offered the opportunity to take part in the clinical investigation at the time of payment and after the eligibility critera have been checked by the pharmacist.

Description

Inclusion Criteria:

• 1. Patient ≥ 12 years,
• 2. Patient with acute rhinitis associated with nasal obstruction during infectious episodes such as rhynopharyngitis (cold), rhinosinusitis, or during non-infectious episodes as allergic rhinitis,
• 3. a. Informed adult patient who has given written consent prior to any study specific procedure,
• b. Informed minor patients who has given assent and whose legal guardians have given written consent prior to any study specific procedure,
• 4. Patient able to meet the study requirements (questionnaire completion),
• 5. Patient affiliated to a social security scheme.

Exclusion Criteria:

• 1. Patient who does not want to participate to the clinical investigation,
• 2. Hypersensitivity to seawater and/or known allergies to any of the ingredients of the spray,
• 3. A child with a history of febrile convulsions,
• 4. Diseases leading to respiratory insufficiency,
• 5. Patient suffering from nasal deformity or nasal polyps leading to chronic nasal obstruction,
• 6. Patient on local ans systemic vasoconstrictors, local and systemic corticosteroids and antihistamines, non-steroidal anti-inflammatory (NSAIDs), antibiotics and local antiseptics,
• 7. Concomitant use of other nasal sprays, essential oils for local nasal use and nsal cream or gel,
• 8. Patient under guardianship, curatorship of safeguard of justice.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Performance of the mechanical decongestant seawater spray enriched with essential oils from Laboratoires Gilbert at 3 days	Proportion of patients presenting a change of the symptom -nasal obstruction- by at least 1 pt, in the SNOT22 Test (item 22), between Day 0 (at inclusion in the pharmacy before using the spray) and Day 3 (in the evening after the last daily use of the spray). This item is scaled form 0 to 5 and 5 is the worst value.	From Day 0 to Day 3

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Performance of the mechanical decongestant seawater spray enriched with essential oils from Laboratoires Gilbert after the first use	Proportion of patients who experienced an amelioration of their nasal obstruction after the first use of the spray at Day 0 on patient questionnaire.	At Day 0
Subjective feeling of reduced nasal obstruction on each day of use	Proportion of patients with a reduction in the symptom -nasal obstruction- of at least 1pt, in the SNOT22 Test (item 22), on each day of use (between Day 0 and Day 6). The item is scaled form 0 to 5 and 5 is the worst value.	From Day 0 and Day 6
Subjective feeling of nasal secretion thinning on each day of use	Proportion of patients presenting a change of the symptom -thick nasal discharge- by at least 1 pt, in the SNOT22 Test, and on each day of use (from Day 0 to Day 6)	From Day 0 to Day 6
Subjective feeling of nasal cavity cleansing (freshness) on each day of use	Proportion of patients who experienced nasal cavity cleansing (feeling of freshness), on Patient Questionnaire, and on each day of use (from Day 0 to Day 6).	From Day 0 to Day 6
Subjective feeling of relief of nasal irritation (mucous membrane) on each day of use	Proportion of patients who experienced relief of nasal irritation (mucous membrane), on Patient Questionnaire, on each day of use (from Day 0 to Day 6).	From Day 0 to Day 6
Subjective feeling of relief of nasal itching on each day of use	Proportion of patients who experienced relief of nasal itching, on Patient Questionnaire, on each day of use (from Day 0 to Day 6).	From Day 0 to Day 6
Subjective feeling of nasal cavity cleansing (freshness) immediately (2 minuts) after the use of the spray at Day 0	Proportion of patient who experienced nasal cavity cleansing (feeling of freshness) immediately (2 minuts) after the use of the spray, on Patient Questionnaire, at Day 0 and Day 6.	At Day 0 and Day 6
Subjective feeling of reduced nasal obstruction immediately (2 minuts) after the use of the spray at Day 6	Proportion of patient who experienced a reduction of nasal obstruction immediately (2 minuts) after the use of the spray, on Patient Questionnaire, at Day 6.	At Day 6
Subjective feeling of reduced nasal obstruction immediately (2 minuts) after the use of the spray at Day 0	Proportion of patient who experienced a reduction of nasal obstruction immediately (2 minuts) after the use of the spray, on Patient Questionnaire, at Day 0.	At Day 0
Improvement in the patient s quality of life after 7 days of use	Proportion of patients who experienced an improvement in quality of life, on Patient Questionnaire (scale of 0-10 with 10 is the best value), between Day 0 and Day 6.	At Day 0 et Day 6
Patient satisfaction with the spray after 7 days of use	Proportion of patients satisfied with the spray on a 4-points scale, at Day 6. The best value is -very satisfied- and the worst value is -very unsatisfied-.	At Day 6
Patient s recommendation of the spray after 7 days of use	Proportion of patients who would recommend the spray, on a 4-points scale, at Day 6. The best value is -definitely yes- and the worst value is -definitely no-.	At Day 6
Patient s willingness to continue using the spray at Day 6	Proportion of patients who will continue to use the spray and the reason if he does not want to continue, on a 4-points scale, at Day 6. The best value is -definitely yes- and the worst value is -definitely no-.	At day 6
Facility of use of the spray after 7 days of use	Proportion of patients who find the spray easy to use, on a 4-points scale, at Day 6. The best value is -very easy- and the worst value is -very difficult-.	At Day 6
Evolution of the overall severity of symptoms	Average SNOT22 score each day and comparison of SNOT22 score at Day 3 versus DAy 0 (baseline). [0 to 220] with 0 is the best value and 220 is the worst value.	At Day 0 and Day 3
Sensations of tingling and transient irritation	Proportion of patients with at least 1 adverse event among : tingling sensation; sensations of transient irritation during the 7 days of use.	From Day 0 to Day 6
All device deficiencies reported by patients using the spray during the 7 days of use	Proportion of patients with at least 1 device deficiency during the clinical investigation.	From Day 0 to Day 6
All adverse events reported by patients using the spray during the 7 days of use	All adverse events reported by the patient during the clinical investigation.	From Day 0 to Day 6

Collaborators and Investigators

• Sponsor: Laboratoires Gilbert
• Collaborators: EVAMED

Study record dates

Study Major Dates

• Study Start (Actual): October 22, 2024
• Primary Completion (Estimated): May 30, 2026
• Study Completion (Estimated): June 7, 2026

Study Registration Dates

• First Submitted: August 29, 2024
• First Submitted That Met QC Criteria: August 29, 2024
• First Posted (Actual): August 30, 2024

Study Record Updates

• Last Update Posted (Actual): November 21, 2025
• Last Update Submitted That Met QC Criteria: November 18, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Stomatognathic Diseases; Immune System Diseases; Respiratory Tract Infections; Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases; Respiration Disorders; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Picornaviridae Infections; Nose Diseases; Otorhinolaryngologic Diseases; Nasopharyngeal Diseases; Pharyngeal Diseases; Respiratory Insufficiency; Rhinitis; Sinusitis; Paranasal Sinus Diseases; Airway Obstruction; Pharyngitis; Rhinosinusitis; Common Cold; Rhinitis, Allergic; Nasal Obstruction; Nasopharyngitis
• Other Study ID Numbers: 2022-A01585-38

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No